Fig. 2From: Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s diseaseOLT1177 increases the clearance of α-synuclein by microglia in vitro. a Representative immunoblotting showing the levels of NLRP3, autophagy-related proteins, and α-synuclein in neonatal microglia. Cells were treated with OLT1177 (OLT, 10 µM) one hour before stimulation with recombinant α-synuclein (α-syn, 10 µM). β-actin was used as loading control. Molecular weight (kDa) is marked on the right side. b–d Quantification of the levels of NLRP3 (b), α-synuclein in the supernatant (c), and lysates (d) at 6 h. e Quantification of the levels of α-synuclein in the lysates of microglial cells after one-hour pulse of recombinant α-synuclein stimulation. f–h Quantification of the levels of p62 (f) and LC3B (g, h) at 6 h. i Quantification of the levels α-synuclein in the lysates after the blockade of Atg5 gene by siRNA (f). Data are pooled from 3 separate experiments and are represented as the mean ± SEM. One-way ANOVA with Tukey’s post hoc correction was used to analyze differences between groups with *p < 0.05, **p < 0.01, and ***p < 0.001Back to article page